DSIP: The "Sleep Peptide" That Never Quite Proved Itself
A clear-eyed look at delta sleep-inducing peptide (DSIP): old, contradictory human data, an unknown mechanism, no modern trials, and why the evidence stays weak.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-07-02A 'sleep peptide' with no confirmed receptor or mechanism, old and contradictory small human trials, and modern preclinical work pointing to stress-protection rather than sleep; unapproved and sold as a research chemical.
No identified gene, receptor or confirmed mechanism; the biology remains speculative.
Modern preclinical work points toward stress-protection rather than sleep.
Human data are old (1981-1992), small and contradictory; the best-controlled trials found benefit too weak to matter.
The name promises more than the data deliver; a placebo explanation cannot be excluded.
Only short-term supervised intravenous dosing was studied; with mechanism and receptor unknown, interactions and hormonal/blood-pressure effects are unpredictable.
No modern rigorous human programme; fringe/very early.
Unknown mechanism and contradictory old data keep confidence very low.
Not approved by any major regulator; nominated to FDA Category 2 as 'Emideltide (DSIP)', nomination later withdrawn — not currently in the active table, which is not a clearance and leaves FDA published immunogenicity, impurity and missing-safety-data concerns standing; sold as an unregulated research chemical.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A 'sleep peptide' whose basic biology is still unsettled — no identified gene, receptor or confirmed mechanism. Human data are old (1981–1992), small and contradictory, and modern work is preclinical and points toward stress-protection rather than sleep.
Safety snapshot
Long-term safety is not established; the small old trials used short-term supervised intravenous dosing, and because the mechanism and receptor are unknown, interactions and hormonal/blood-pressure effects are unpredictable. It may also simply not work (placebo).
Regulatory & legality
Not approved by any major regulator. The FDA lists the substance as 'Emideltide (DSIP)' among bulk substances nominated to Category 2 whose nominations were withdrawn, so it is not currently in the active Category 2 table; a withdrawal is not approval or clearance and the FDA still publishes the concerns it identified, namely possible immunogenicity for certain routes, impurity and characterisation complexity, and no identified safety information for the proposed route. Sold as an unregulated research chemical.
Where claims can exceed the evidence
The name promises more than the data deliver — the best-controlled trials found benefit too weak to matter, and there are no rigorous modern human trials.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Delta sleep-inducing peptide (DSIP) is one of the most intriguing and most disappointing compounds in the peptide world. It arrives with a fantastic name, a fifty-year backstory, and a promise baked right into its title: a molecule your brain supposedly makes to switch on deep, restorative sleep. The reality is far messier.
DSIP was isolated in 1977 from the cerebral venous blood of rabbits and proposed as an endogenous sleep factor [10]. The early human work, mostly from one Swiss group in Basel, looked genuinely promising. But when independent teams tried to replicate it under properly controlled conditions, the effect largely evaporated [6][8]. Decades later, the molecule's basic biology is still unsettled: no one has found its gene, its receptor, or even confirmed that DSIP reliably causes the deep sleep it is named after [9].
If you are an informed self-experimenter weighing DSIP, the honest summary is this: the evidence is old, small, contradictory, and mostly preclinical. What follows is the full picture, with the gaps left visible.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
Melatonin: A Clock-Setter, Not a Sledgehammer
Melatonin is strong evidence for jet lag and circadian disorders but only modest for adult insomnia — timing matters more than dose.
Selank: A Calm-Without-Sedation Peptide With a Russian Evidence Base
A plain-English look at Selank, the tuftsin-derived anxiolytic peptide: how it works, what the (largely Russian) research shows, doses studied, and honest limits.
Semax: A Russian Brain Peptide With Strong Animal Data and Thin Human Proof
Semax boosts BDNF and modulates dopamine and serotonin in rodents, but human evidence is small, Russian-only, and mostly stroke-focused — not nootropic.